NO20060032L - Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter - Google Patents
Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekterInfo
- Publication number
- NO20060032L NO20060032L NO20060032A NO20060032A NO20060032L NO 20060032 L NO20060032 L NO 20060032L NO 20060032 A NO20060032 A NO 20060032A NO 20060032 A NO20060032 A NO 20060032A NO 20060032 L NO20060032 L NO 20060032L
- Authority
- NO
- Norway
- Prior art keywords
- growth factor
- hypercholesterolemia
- diabetes
- fibroblast growth
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Sammendrag Denne oppfinnelsen gjelder bruken av et plasmid som koder for en vekstfaktor for fibroblast (heretter kalt "fibroblastvekstfaktor") som terapeutisk middel for forebygging og behandling av hyperkolesterolemi eller diabetes forbundet med angiogeniske defekter i myokardium eller skjelett. Denne oppfinnelsen gjelder også en metode for å forbedre dannelsen av både kollaterale blodkar og arterioler i de iskemiske vevene i myokardium eller skjelettet på et pattedyr som lider av hyperkolesterolemi eller diabetes. Denne oppfinnelsen gjelder også en fremgangsmåte for å fremme dannelsen av kollaterale blodkar i iskemiske vev i myokardium eller skjelettet uten å utløse VEGF-A-faktorekspresjon (vascular endothelial growth factor) og forårsake ødem i de behandlede musklene.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47595903P | 2003-06-05 | 2003-06-05 | |
US56091504P | 2004-04-09 | 2004-04-09 | |
US56619304P | 2004-04-28 | 2004-04-28 | |
PCT/EP2004/006903 WO2004108167A1 (en) | 2003-06-05 | 2004-06-04 | Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060032L true NO20060032L (no) | 2006-01-04 |
Family
ID=33514717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060032A NO20060032L (no) | 2003-06-05 | 2006-01-04 | Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter |
Country Status (11)
Country | Link |
---|---|
US (1) | US20050096286A1 (no) |
EP (1) | EP1677831A1 (no) |
JP (1) | JP2006526592A (no) |
KR (1) | KR20060052692A (no) |
AU (2) | AU2004244756A1 (no) |
BR (1) | BRPI0410844A (no) |
CA (1) | CA2526792A1 (no) |
EA (1) | EA200501846A1 (no) |
NO (1) | NO20060032L (no) |
NZ (1) | NZ543717A (no) |
WO (1) | WO2004108167A1 (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7038026B2 (en) | 2000-05-26 | 2006-05-02 | Centelion | Purification of a triple heli formation with an immobilized oligonucleotide |
US7279313B2 (en) | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
FR2822476B1 (fr) | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice |
MXPA06007519A (es) * | 2003-12-29 | 2007-05-23 | Centelion | Tratamiento de la isquemia coronaria o periferica. |
AU2007212260A1 (en) * | 2006-02-09 | 2007-08-16 | Sangamo Therapeutics, Inc. | Method for treating peripheral arterial disease with zinc finger proteins |
RU2573896C2 (ru) * | 2009-10-15 | 2016-01-27 | Дженентек, Инк. | Химерные факторы роста фибробластов с измененной рецепторной специфичностью |
EP2558115B1 (en) * | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Methods for treating metabolic disorders using fgf |
US9925241B2 (en) | 2013-10-21 | 2018-03-27 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
JP2018535964A (ja) | 2015-10-30 | 2018-12-06 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置 |
US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
US11746352B2 (en) * | 2019-12-30 | 2023-09-05 | Eligo Bioscience | Microbiome modulation of a host by delivery of DNA payloads with minimized spread |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692435A (en) * | 1978-11-06 | 1987-09-08 | Choay, S.A. | Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation |
CA1136620A (en) * | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
IL72058A (en) * | 1984-06-08 | 1988-03-31 | Ram Lavie | Method for heat and mass exchange operations |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4686113A (en) * | 1985-12-18 | 1987-08-11 | Fairchild Semiconductor Corporation | Plasma confinement in a low pressure electrically grounded R.F. heated reactor and deposition method |
US5827826A (en) * | 1986-03-03 | 1998-10-27 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compositions of human endothelial cell growth factor |
ZA874487B (en) * | 1986-06-23 | 1987-12-23 | Merck & Co.,Inc. | Novel hmg-coa reductase inhibitors |
CA1322163C (en) * | 1986-07-03 | 1993-09-14 | Kenneth A. Thomas, Jr. | Plasminogen activator production |
US5045565A (en) * | 1987-03-09 | 1991-09-03 | The Procter & Gamble Company | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain |
US4965200A (en) * | 1989-06-23 | 1990-10-23 | Merck & Co., Inc. | Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs |
FR2663639B1 (fr) * | 1990-06-26 | 1994-03-18 | Rhone Poulenc Sante | Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation. |
WO1993008828A1 (en) * | 1991-11-08 | 1993-05-13 | Syntex-Synergen Neuroscience Joint Venture | Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
US6086582A (en) * | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
WO1999001150A1 (en) * | 1997-07-03 | 1999-01-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel composition for treating, preventing and/or delaying ischemic cell death |
ES2255155T3 (es) * | 1998-02-05 | 2006-06-16 | Biosense Webster, Inc. | Dispositivo para la administracion intracardiaca de farmacos. |
US20020122792A1 (en) * | 1998-07-24 | 2002-09-05 | Thomas J. Stegmann | Induction of neoangiogenesis in ischemic myocardium |
US6102887A (en) * | 1998-08-11 | 2000-08-15 | Biocardia, Inc. | Catheter drug delivery system and method for use |
US20010034023A1 (en) * | 1999-04-26 | 2001-10-25 | Stanton Vincent P. | Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing |
US20020037508A1 (en) * | 2000-01-19 | 2002-03-28 | Michele Cargill | Human single nucleotide polymorphisms |
US6988004B2 (en) * | 2000-05-16 | 2006-01-17 | Bioheart, Inc. | Method for inducing angiogenesis by electrical stimulation of muscles |
AU8825601A (en) * | 2000-08-15 | 2002-02-25 | Phage Biotechnology Corp | A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
WO2002046220A2 (en) * | 2000-12-07 | 2002-06-13 | Gencell S.A. | Sequences upstream of the carp gene, vectors containing them and uses thereof |
-
2004
- 2004-06-04 WO PCT/EP2004/006903 patent/WO2004108167A1/en active Application Filing
- 2004-06-04 JP JP2006508289A patent/JP2006526592A/ja active Pending
- 2004-06-04 AU AU2004244756A patent/AU2004244756A1/en not_active Abandoned
- 2004-06-04 CA CA002526792A patent/CA2526792A1/en not_active Abandoned
- 2004-06-04 BR BRPI0410844-2A patent/BRPI0410844A/pt not_active IP Right Cessation
- 2004-06-04 NZ NZ543717A patent/NZ543717A/en unknown
- 2004-06-04 KR KR1020057023058A patent/KR20060052692A/ko not_active Application Discontinuation
- 2004-06-04 EA EA200501846A patent/EA200501846A1/ru not_active IP Right Cessation
- 2004-06-04 EP EP04740314A patent/EP1677831A1/en not_active Withdrawn
- 2004-06-07 US US10/861,906 patent/US20050096286A1/en not_active Abandoned
-
2006
- 2006-01-04 NO NO20060032A patent/NO20060032L/no not_active Application Discontinuation
-
2010
- 2010-12-22 AU AU2010257389A patent/AU2010257389A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20050096286A1 (en) | 2005-05-05 |
BRPI0410844A (pt) | 2006-06-27 |
AU2010257389A1 (en) | 2011-01-27 |
EP1677831A1 (en) | 2006-07-12 |
CA2526792A1 (en) | 2004-12-16 |
NZ543717A (en) | 2008-06-30 |
JP2006526592A (ja) | 2006-11-24 |
AU2004244756A1 (en) | 2004-12-16 |
KR20060052692A (ko) | 2006-05-19 |
EA009390B1 (ru) | 2007-12-28 |
WO2004108167A1 (en) | 2004-12-16 |
EA200501846A1 (ru) | 2007-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060032L (no) | Plasmid som koder for fibroblastvekstfaktor for behandling av hyperkolesterolemi eller diabetesrelaterte angiogeniske defekter | |
WO2002064157A3 (en) | Localized myocardial injection method for treating ischemic myocardium | |
Cutlip et al. | Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction | |
WO2001013031A3 (en) | Dose of an angiogenic factor and method of administering to improve myocardial blood flow | |
WO2006121532A3 (en) | Treatment for heart disease | |
PT1267897E (pt) | Tratamento da insufuciencia cardiaca congestiva com sangue autologo previamente tratado | |
WO2002089856A8 (en) | Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery | |
WO2002004008A3 (en) | Methods of therapy with thrombin derived peptides | |
WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
WO2002000210A3 (en) | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease | |
Liu et al. | Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery | |
PT804229E (pt) | Utilizacao de amlodipina de um dos seus sais ou defelodipina em combinacao com um inibidor da en zima de conversao da angiotensina (ace) para no fabrico de um medicamento destinado ao tratamento da insuficiencia cardiaca congestiva nao isquemica | |
Alunni et al. | The beneficial effect of extracorporeal shockwave myocardial revascularization: Two years of follow-up | |
Pavone et al. | Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study | |
Gowda et al. | Treatment of refractory angina pectoris | |
EA200200533A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo | |
Garg et al. | Acute myocardial infarction secondary to thromboembolism in a patient with atrial fibrillation | |
Goldhaber et al. | Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator | |
Zhao et al. | Remote periconditioning reduces myocardial no-reflow by the activation of KATP channel via inhibition of Rho-kinase | |
Nademanee et al. | Long-term antithrombotic treatment for atrial fibrillation | |
AU655780B2 (en) | A method and composition for the protection of a metabolic recovery of ischemic cardiac tissue | |
Herlitz et al. | Delay time between onset of myocardial infarction and start of thrombolysis in relation to prognosis | |
WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
NO20021410L (no) | Forebygging og behandling av blodkoagulasjons-relaterte sykdommer | |
NO20005223L (no) | Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |